Connecta Therapeutics
Dr. Hagerman is internationally recognized as both a clinician and researcher in the fragile X field. She has carried out multiple targeted treatment trials in FXS and autism including a controlled trial of Arbaclofen, minocycline, ganaxolone, mGluR5 antagonists developed by Roche and by Novartis, and sertraline.
This person is not in the org chart
This person is not in any teams
This person is not in any offices